Clinical trials: Epigenetic Therapy
Polycystic Ovary Syndrome
Ovary Syndrome for Efficient Diagnosis and Targeted Therapy
OBJECTIVES: 1. Analysis of DNA methyl transferases (DNMT1, DNMT3A and DNMT3B) and Histone deacetylases (HDAC 1,2,3 and SIRTs) polymorphisms (Somatic and germ line variations). 2.
- Trial name
- PCOS-01 (NCT06102629)
- Testing
- laparoscopy / laparotomy, NO INTERVENTION
- Where
- India
- Volunteers
- 200 people
- Sponsor
- Asian Institute of Gastroenterology, India
Childhood Cancer
Epigenetic and Metabolomic Changes in Childhood Cancer Survivors
The purpose of this research study is to try and identify markers in childhood cancer survivors to help predict if they will develop late effects from their cancer treatment.
- Trial name
- NCT03866707
- Testing
- One-time blood draw, Evaluation of CpG methylation, Metabolomic analysis
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Cortisol Excess, Stress, Psychological
Effects of "Vitamin N" Nature Immersion Therapy on Stress Levels in Health Care Workers in the City of Bogotá
Recent studies on health personnel in Colombia have evidenced the considerable increase in the levels of stress and anxiety, among other psychological disorders, as a product of the COVID-19 pandemic that is being experienced…
- Conditions
- Cortisol Excess, Stress, Psychological, Anxiety, Epigenetic Disorder
- Trial name
- NCT05315388
- Testing
- Immersion therapy in nature - Vitamin N
- Where
- Colombia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Jeadran N. Malagón-Rojas
AML, Adult, Myelodysplastic Syndromes
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
This open-label Phase I study aims to define the recommended dose for further clinical development the NKR-2 treatment administered concurrently with AZA in treatment-naïve AML/MDS patients not candidates for intensive…
- Trial name
- EPITHINK (NCT03612739)
- Testing
- NKR-2 CAR-T Cells
- Sponsor
- Celyad Oncology SA
Head and Neck Cancer
Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches in Head and Neck Cancer
Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9).
- Trial name
- AIRC-Chiocca (NCT06706973)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Acute Myeloid Leukemia
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
The long-term outcome of patients with acute myeloid leukemia (AML) remains poor, with less than 30% of patients achieving long lasting remission or cure.
- Trial name
- TEAM (NCT04173585)
- Testing
- Bortezomib, Gemtuzumab Ozogamicin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Heidelberg
Facioscapulohumeral Muscular Dystrophy
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy…
- Trial name
- FSHD (NCT06907875)
- Testing
- EPI-321
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- Epicrispr Biotechnologies, Inc.
High-risk Prostate Cancer
A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical…
- Trial name
- NCT06888102
- Testing
- Neoadjuvant Epigenetic Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Edwin Posadas, MD
Ovarian Cancer
Hydralazine Valproate for Ovarian Cancer
The current standard for recurrent, persistent or metastatic cisplatin-resistant ovarian cancer is palliative chemotherapy with either topotecan, liposomal doxorubicin or gemcitabine, however, the results need to be improved.
- Trial name
- NCT00533299
- Testing
- Hydralazine and magnesium valproate
- Where
- Mexico
- Volunteers
- 211 people
- Sponsor
- National Institute of Cancerología
Metastatic Melanoma, Melanoma
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
- Conditions
- Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
- Trial name
- ML28604 (NCT01876641)
- Testing
- Vemurafenib + Cobimetinib, Decitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mohammed M Milhem
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)
The objective of the phase I part of the trial is the determination of the maximum tolerated dose (MTD) of TCP (Tranylcypromine) in combination with fixed-dose ATRA (all-trans-retinoic acid) and with fixed-dose AraC (Cytarabine)…
- Trial name
- TRANSATRA (NCT02717884)
- Testing
- tranylcypromine, all-trans retinoic acid, cytarabine
- Where
- 6 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Michael Luebbert
Chronic Hepatitis B
Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance
Achieving a functional cure for chronic hepatitis B (CHB) is largely hindered by the irreversible functional exhaustion and immune tolerance of hepatitis B virus (HBV)-specific CD8 positive T (CD8+ T) cells.
- Trial name
- NCT07777250
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Municipal Administration of Hospitals
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Lung Cancer, Non-small Cell Lung Cancer
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
The purpose of this study is to assess whether treatment with the study drug tetrahydrouridine-decitabine (THU-Dec) in combination with nivolumab is more effective than treatment with nivolumab alone in patients with NSCLC.
- Trial name
- PRECISE (NCT02664181)
- Testing
- Nivolumab, oral decitabine, Tetrahydrouridine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Stroke Rehabilitation
Post Stroke Intensive Rehabilitation
Prospective observational cohort study, with 6 months follow up, to identify clinical, instrumental and genetic predictors of functional recovery in hospitalized patients undergoing intensive rehabilitation after stroke.
- Trial name
- PSR (NCT03866057)
- Where
- Italy
- Volunteers
- 270 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Pancreatic Cancer
Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)
To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as…
- Trial name
- NCT01845805
- Testing
- oral azacitidine, Observation
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Schizophrenia, Schizoaffective Disorder
Open-label Study of Curcumin C-3 Complex in Schizophrenia
Current evidence suggests that schizophrenia as a serious and complex psychiatric disorder, continues to challenge mental health professionals in their search for better treatment options in the community.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depression
- Trial name
- NCT01875822
- Testing
- Super-Curcumin
- Where
- Puerto Rico
- Volunteers
- 17 people
- Sponsor
- Woodbury, Michel, M.D.
Aging
A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging
This study aims to assess the impact of hyperbaric oxygen therapy on a number of outcomes, including epigenetic aging, inflammation, and cellular health.
- Trial name
- HBOT (NCT05297019)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Female Infertility, Gene Deregulation
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment
There is increasing evidence that exposure to environmental factors in early development is associated with an increased risk of metabolic and other common diseases.
- Trial name
- NCT03565107
- Where
- Germany
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Infertility Treatment Center Dortmund